No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy

Hwa-ping Feng(Merck & Co., Inc., Rahway, NJ, USA (United States)), Wendy W. Yeh(VIR Biotechnology (United States)), Iain P. Fraser(Merck & Co., Inc., Rahway, NJ, USA (United States)), Lynn R. Webster(Adherent Technologies (United States)), Joan R. Butterton(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert Valesky(Merck & Co., Inc., Rahway, NJ, USA (United States)), Deborah Panebianco(Merck & Co., Inc., Rahway, NJ, USA (United States)), Marian Iwamoto(Merck & Co., Inc., Rahway, NJ, USA (United States)), Patricia Jumes(Merck & Co., Inc., Rahway, NJ, USA (United States)), Christina Reitmann(Merck & Co., Inc., Rahway, NJ, USA (United States)), Luzelena Caro(Merck & Co., Inc., Rahway, NJ, USA (United States)), Fang Liu(China University of Mining and Technology), William L. Marshall(University of Louisville), Zifang Guo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Monika Martinho(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dennis Wolford(MACOM (United States)), Pavan Vaddady(Merck & Co., Inc., Rahway, NJ, USA (United States))
Clinical and Translational Science
July 24, 2018
10.1111/cts.12564
Cited by 14

Related Papers

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
Predicting Aberrant Behaviors in Opioid-Treated Patients: Preliminary Validation of the Opioid Risk Tool
|Pain Medicine|2005|1.1k
Risk Factors for Opioid-Use Disorder and Overdose
|Anesthesia & Analgesia|2017|504
Naloxegol for Opioid-Induced Constipation in Patients with Noncancer Pain
|New England Journal of Medicine|2014|331
Sleep-Disordered Breathing and Chronic Opioid Therapy
|Pain Medicine|2007|309